- Home
- PRVA vs AAPG Comparison
PRVA vs AAPG Comparison
Compare PRVA & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRVA | AAPG |
|---|---|---|
| Founded | 2007 | 2009 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.6B |
| IPO Year | 2021 | 2025 |
Fundamental Metrics
Financial Performance| Metric | PRVA | AAPG |
|---|---|---|
| Price | $23.29 | $26.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 5 |
| Target Price | $30.50 | ★ $48.50 |
| AVG Volume (30 Days) | ★ 634.0K | 3.7K |
| Earning Date | 02-26-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.88 | N/A |
| EPS | ★ 0.14 | N/A |
| Revenue | ★ $2,042,569,000.00 | $54,524,554.00 |
| Revenue This Year | $104.97 | N/A |
| Revenue Next Year | $9.92 | $368.64 |
| P/E Ratio | $170.33 | ★ N/A |
| Revenue Growth | ★ 19.01 | N/A |
| 52 Week Low | $18.77 | $16.50 |
| 52 Week High | $26.51 | $48.45 |
Technical Indicators
Market Signals| Indicator | PRVA | AAPG |
|---|---|---|
| Relative Strength Index (RSI) | 45.90 | 42.22 |
| Support Level | $22.59 | $27.48 |
| Resistance Level | $24.00 | $28.49 |
| Average True Range (ATR) | 0.74 | 0.49 |
| MACD | -0.04 | 0.21 |
| Stochastic Oscillator | 35.32 | 37.17 |
Price Performance
Historical ComparisonAbout PRVA Privia Health Group Inc.
Privia Health Group Inc is a technology-driven, national physician-enablement company. It collaborates with medical groups, health plans, and health systems to optimize physician practices, improve patient experiences, and reward doctors for delivering high-value care in both in-person and virtual care settings.
About AAPG Ascentage Pharma Group International American Depository Shares
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.